These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12148000)

  • 41. Deal watch: Trends in platform technology deal-making.
    Walker J; Jacob J
    Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
    [No Abstract]   [Full Text] [Related]  

  • 42. The importance of cell physiology to the performance of animal cell bioreactors.
    Runstadler PW
    Ann N Y Acad Sci; 1992 Oct; 665():380-90. PubMed ID: 1416616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins.
    Eldering JA; Felten C; Veilleux CA; Potts BJ
    Biologicals; 2004 Dec; 32(4):183-93. PubMed ID: 15572100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Commercial development of microalgal biotechnology: from the test tube to the marketplace.
    Olaizola M
    Biomol Eng; 2003 Jul; 20(4-6):459-66. PubMed ID: 12919832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overproduction of recombinant human VEGF (vascular endothelial growth factor) in Chinese hamster ovary cells.
    Lee SB; Park JS; Lee S; Park J; Yu S; Kim H; Kim D; Byun TH; Baek K; Ahn YJ; Yoon J
    J Microbiol Biotechnol; 2008 Jan; 18(1):183-7. PubMed ID: 18239438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel orbital shake bioreactors for transient production of CHO derived IgGs.
    Stettler M; Zhang X; Hacker DL; De Jesus M; Wurm FM
    Biotechnol Prog; 2007; 23(6):1340-6. PubMed ID: 17914862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical engineering.
    Carrondo MJ; Aunins JG
    Curr Opin Biotechnol; 2004 Oct; 15(5):441-3. PubMed ID: 15464375
    [No Abstract]   [Full Text] [Related]  

  • 48. Plant-based production of biopharmaceuticals.
    Fischer R; Stoger E; Schillberg S; Christou P; Twyman RM
    Curr Opin Plant Biol; 2004 Apr; 7(2):152-8. PubMed ID: 15003215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural products as lead-structures: a role for biotechnology.
    John JE
    Drug Discov Today; 2010 Jun; 15(11-12):409-10. PubMed ID: 20206288
    [No Abstract]   [Full Text] [Related]  

  • 50. Downstream processing of recombinant proteins from transgenic feedstock.
    Nikolov ZL; Woodard SL
    Curr Opin Biotechnol; 2004 Oct; 15(5):479-86. PubMed ID: 15464381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Special issue on the production of recombinant proteins.
    Sanchez S; Demain A
    Biotechnol Adv; 2012; 30(5):1100-1. PubMed ID: 22227398
    [No Abstract]   [Full Text] [Related]  

  • 52. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant expression systems in the pharmaceutical industry.
    Schmidt FR
    Appl Microbiol Biotechnol; 2004 Sep; 65(4):363-72. PubMed ID: 15480623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A guide to drug discovery: Target selection in drug discovery.
    Knowles J; Gromo G
    Nat Rev Drug Discov; 2003 Jan; 2(1):63-9. PubMed ID: 12509760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transgenic animals for the production of biological medicines.
    Minor PD
    Dev Biol (Basel); 2004; 118():165-9. PubMed ID: 15645687
    [No Abstract]   [Full Text] [Related]  

  • 56. A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies.
    Xenopoulos A
    J Biotechnol; 2015 Nov; 213():42-53. PubMed ID: 25959171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 58. Industrial biotechnology for the production of bio-based chemicals--a cradle-to-grave perspective.
    Hatti-Kaul R; Törnvall U; Gustafsson L; Börjesson P
    Trends Biotechnol; 2007 Mar; 25(3):119-24. PubMed ID: 17234288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Health security--GMOs in therapeutics].
    Trouvin JH
    Ann Pharm Fr; 2003 Mar; 61(2):103-8. PubMed ID: 12668948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium.
    Link T; Bäckström M; Graham R; Essers R; Zörner K; Gätgens J; Burchell J; Taylor-Papadimitriou J; Hansson GC; Noll T
    J Biotechnol; 2004 May; 110(1):51-62. PubMed ID: 15099905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.